Bioventus (BVS) Total Non-Current Liabilities (2020 - 2026)

Bioventus (BVS) has 7 years of Total Non-Current Liabilities data on file, last reported at $402.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities fell 16.94% year-over-year to $402.0 million; the trailing twelve-month figure through Mar 2026 stood at $402.0 million (down 16.94% YoY), and the FY2025 full-year result was $439.8 million, down 15.31% from the prior year.
• Total Non-Current Liabilities for Q1 2026 stood at $402.0 million, down from $439.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $994.6 million in Q4 2022 and bottomed at $402.0 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $561.9 million (2023), against an average of $595.3 million.
• The widest annual swing landed in 2022, when Total Non-Current Liabilities soared 147.58%; it then slumped 44.33% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $943.0 million in 2022, then tumbled by 40.42% to $561.9 million in 2023, then declined by 7.58% to $519.2 million in 2024, then declined by 15.31% to $439.8 million in 2025, then fell by 8.59% to $402.0 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $402.0 million (Q1 2026), $439.8 million (Q4 2025), and $473.9 million (Q3 2025), per Business Quant data.

Peer Comparison